Global Moderna Vaccine Market
Global Moderna Vaccine Market

Moderna Vaccine Comprehensive Study by End User (Laboratories, Hospitals, Diagnostic Centers and Clinics, Research Institutes, Others) Players and Region - Global Market Outlook to 2026

Moderna Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 232 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Moderna Vaccine Market Overview:
COVID-19 Vaccine Moderna is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 Vaccine Moderna contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. COVID-19 Vaccine Moderna does not contain the virus itself and cannot cause COVID-19.COVID-19 Vaccine Moderna is given as two injections, usually into the muscle of the upper arm, 28 days apart

Growth Drivers
  • Growing Strategic Partnerships among Various Biotech and Pharmaceutical Firms
  • Rising Number of Geriatric Population and People Suffering from Preexisting Conditions including Respiratory Conditions, Diabetes, and Heart Diseases

Market Trends
  • Growing Funding for Research and Development Activities to Develop the Moderna Vaccine

Roadblocks
  • Uncertainty in the Efficacy and Side Effects of Repurposed Malaria Drugs Targeting COVID-19

Opportunities
  • Adoption of New Tools to Expedite Drug Discovery
  • Investments in Real-world Evidence by Pharmaceutical Companies

Challenges
  • Strict Government Rules and Regulations


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Moderna, Inc. (United States), CureVac (Germany) and BioNTech (Germany). Considering Market by End User, the sub-segment i.e. Laboratories will boost the Moderna Vaccine market.

In Nov 2020, Moderna, Inc. announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Moderna Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Moderna Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Moderna Vaccine Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By End User
  • Laboratories
  • Hospitals
  • Diagnostic Centers and Clinics
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Strategic Partnerships among Various Biotech and Pharmaceutical Firms
      • 3.2.2. Rising Number of Geriatric Population and People Suffering from Preexisting Conditions including Respiratory Conditions, Diabetes, and Heart Diseases
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Growing Funding for Research and Development Activities to Develop the Moderna Vaccine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Moderna Vaccine, by End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Moderna Vaccine (Value)
      • 5.2.1. Global Moderna Vaccine by: End User (Value)
        • 5.2.1.1. Laboratories
        • 5.2.1.2. Hospitals
        • 5.2.1.3. Diagnostic Centers and Clinics
        • 5.2.1.4. Research Institutes
        • 5.2.1.5. Others
      • 5.2.2. Global Moderna Vaccine Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Moderna Vaccine (Price)
  • 6. Moderna Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Moderna, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CureVac (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioNTech (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
  • 7. Global Moderna Vaccine Sale, by End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Moderna Vaccine (Value)
      • 7.2.1. Global Moderna Vaccine by: End User (Value)
        • 7.2.1.1. Laboratories
        • 7.2.1.2. Hospitals
        • 7.2.1.3. Diagnostic Centers and Clinics
        • 7.2.1.4. Research Institutes
        • 7.2.1.5. Others
      • 7.2.2. Global Moderna Vaccine Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Moderna Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Moderna Vaccine: by End User(USD Million)
  • Table 2. Moderna Vaccine Laboratories , by Region USD Million (2015-2020)
  • Table 3. Moderna Vaccine Hospitals , by Region USD Million (2015-2020)
  • Table 4. Moderna Vaccine Diagnostic Centers and Clinics , by Region USD Million (2015-2020)
  • Table 5. Moderna Vaccine Research Institutes , by Region USD Million (2015-2020)
  • Table 6. Moderna Vaccine Others , by Region USD Million (2015-2020)
  • Table 7. South America Moderna Vaccine, by Country USD Million (2015-2020)
  • Table 8. South America Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 9. Brazil Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 10. Argentina Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 11. Rest of South America Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 12. Asia Pacific Moderna Vaccine, by Country USD Million (2015-2020)
  • Table 13. Asia Pacific Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 14. China Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 15. Japan Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 16. India Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 17. South Korea Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 18. Taiwan Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 19. Australia Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 20. Rest of Asia-Pacific Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 21. Europe Moderna Vaccine, by Country USD Million (2015-2020)
  • Table 22. Europe Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 23. Germany Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 24. France Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 25. Italy Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 26. United Kingdom Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 27. Netherlands Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 28. Rest of Europe Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 29. MEA Moderna Vaccine, by Country USD Million (2015-2020)
  • Table 30. MEA Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 31. Middle East Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 32. Africa Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 33. North America Moderna Vaccine, by Country USD Million (2015-2020)
  • Table 34. North America Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 35. United States Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 36. Canada Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 37. Mexico Moderna Vaccine, by End User USD Million (2015-2020)
  • Table 38. Company Basic Information, Sales Area and Its Competitors
  • Table 39. Company Basic Information, Sales Area and Its Competitors
  • Table 40. Company Basic Information, Sales Area and Its Competitors
  • Table 41. Moderna Vaccine: by End User(USD Million)
  • Table 42. Moderna Vaccine Laboratories , by Region USD Million (2021-2026)
  • Table 43. Moderna Vaccine Hospitals , by Region USD Million (2021-2026)
  • Table 44. Moderna Vaccine Diagnostic Centers and Clinics , by Region USD Million (2021-2026)
  • Table 45. Moderna Vaccine Research Institutes , by Region USD Million (2021-2026)
  • Table 46. Moderna Vaccine Others , by Region USD Million (2021-2026)
  • Table 47. South America Moderna Vaccine, by Country USD Million (2021-2026)
  • Table 48. South America Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 49. Brazil Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 50. Argentina Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 51. Rest of South America Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 52. Asia Pacific Moderna Vaccine, by Country USD Million (2021-2026)
  • Table 53. Asia Pacific Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 54. China Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 55. Japan Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 56. India Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 57. South Korea Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 58. Taiwan Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 59. Australia Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 60. Rest of Asia-Pacific Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 61. Europe Moderna Vaccine, by Country USD Million (2021-2026)
  • Table 62. Europe Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 63. Germany Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 64. France Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 65. Italy Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 66. United Kingdom Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 67. Netherlands Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 68. Rest of Europe Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 69. MEA Moderna Vaccine, by Country USD Million (2021-2026)
  • Table 70. MEA Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 71. Middle East Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 72. Africa Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 73. North America Moderna Vaccine, by Country USD Million (2021-2026)
  • Table 74. North America Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 75. United States Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 76. Canada Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 77. Mexico Moderna Vaccine, by End User USD Million (2021-2026)
  • Table 78. Research Programs/Design for This Report
  • Table 79. Key Data Information from Secondary Sources
  • Table 80. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Moderna Vaccine: by End User USD Million (2015-2020)
  • Figure 5. South America Moderna Vaccine Share (%), by Country
  • Figure 6. Asia Pacific Moderna Vaccine Share (%), by Country
  • Figure 7. Europe Moderna Vaccine Share (%), by Country
  • Figure 8. MEA Moderna Vaccine Share (%), by Country
  • Figure 9. North America Moderna Vaccine Share (%), by Country
  • Figure 10. Global Moderna Vaccine share by Players 2020 (%)
  • Figure 11. BCG Matrix for key Companies
  • Figure 12. Moderna, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 13. Moderna, Inc. (United States) Revenue: by Geography 2020
  • Figure 14. CureVac (Germany) Revenue, Net Income and Gross profit
  • Figure 15. CureVac (Germany) Revenue: by Geography 2020
  • Figure 16. BioNTech (Germany) Revenue, Net Income and Gross profit
  • Figure 17. BioNTech (Germany) Revenue: by Geography 2020
  • Figure 18. Global Moderna Vaccine: by End User USD Million (2021-2026)
  • Figure 19. South America Moderna Vaccine Share (%), by Country
  • Figure 20. Asia Pacific Moderna Vaccine Share (%), by Country
  • Figure 21. Europe Moderna Vaccine Share (%), by Country
  • Figure 22. MEA Moderna Vaccine Share (%), by Country
  • Figure 23. North America Moderna Vaccine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Moderna, Inc. (United States)
  • CureVac (Germany)
  • BioNTech (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation